Thimble Point Acquisition Corp

Pear Therapeutics, Inc. is a commercial-stage healthcare company pioneering a new class of software-based medicines, sometimes referred to as Prescription Digital Therapeutics (PDT), which use software to treat diseases directly. The firm aims to redefine medicine by discovering, developing, and delivering clinically validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. It has a pipeline of products and product candidates across therapeutic areas, including the first three PDTs with disease treatment claims from the FDA. The company’s lead product, reSET, for the treatment of substance use disorder, was the first PDT to receive marketing authorization from the FDA to treat disease. Its second product, reSET-O, for the treatment of opioid use disorder, was the first PDT to receive Breakthrough Designation. Pear's third product, Somryst for the treatment of chronic insomnia, was the first PDT submitted through the FDA's traditional 510(k) pathway while simultaneously reviewed through the FDA's Software Precertification Pilot Program. The company was founded on December 1, 2020 and is headquartered in Boston, MA.

The full company name is Sanswire Technologies Inc.

BOSTON--(BUSINESS WIRE)--Pear Announces Operational Performance Metrics for Full Year 2021; Reaffirms Financial and Operational Performance Metrics for Full Year 2022

Pear Therapeutics Announces Operational Performance Metrics for Full Year 2021 and Reaffirms Financial and Operational Performance Metrics for Full Year 2022

BOSTON & CANTON, Mass.--(BUSINESS WIRE)--Pear Therapeutics to Further Support Point32Health Members in Recovery from Substance Use Disorders

Pear Therapeutics to Further Support Point32Health Members in Recovery from Substance Use Disorders

Pear is a category creator of Digital Therapeutics (DTx), which means its applications are reimbursed at phenomenal rates by payors and other benefit providers. The addressable market in the US alone is massive with Pear's treatment areas, and Pear is first out the gate.

Even With Low Penetration Assumptions For PDTs, Pear Therapeutics Is A Buy

Shares of Pear Therapeutics Inc (NASDAQ: PEAR) closed up nearly 25% on Monday after BTIG said the Boston-headquartered company was the best positioned in the prescription digital therapeutics (PDT) space. BTIG's Marie Thibault sees a 60% upside On Monday, analyst Marie Thibault assumed coverage of the stock with a “buy” rating and a price target […] The post Pear Therapeutics closed up 25% on Monday: explained here appeared first on Invezz.

Pear Therapeutics closed up 25% on Monday: explained here

BTIG initiated coverage of Pear Therapeutics Inc (NASDAQ:PEAR) with a Buy rating and $12 price target, representing an upside of almost 55%. Analyst Marie Thibault believes Pear is one of the best-positioned companies in the prescription digital therapeutics space.

Read Why BTIG Sees An Upside OF 55% In Pear Therapeutics

Pear Therapeutics Inc (NASDAQ:PEAR) is trading higher Monday following positive analyst coverage from BTIG. BTIG analyst Marie Thibault initiated coverage on Pear Therapeutics with a Buy rating and announced a $12 price target.

Why Pear Therapeutics Stock Is Rising Today

Accuray

Grab Holdings Ltd

Bionano Genomics

Innovid Corp

While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

5 Buy-Rated Stocks Trading Under $10 With Huge 2022 New Year's Potential

BOSTON--(BUSINESS WIRE)--Pear Therapeutics Announces the Acquisition of Two Assets Addressing a Comprehensive Spectrum of Depression Conditions

Pear Therapeutics Announces the Acquisition of Two Assets Addressing a Comprehensive Spectrum of Depression Conditions

BOSTON--(BUSINESS WIRE)--Pear and Crossroads to Provide More Patients Access to PDTs as Standard of Care for the Treatment of Substance Use Disorders

Pear Therapeutics and Crossroads Treatment Centers to Provide More Patients Access to Prescription Digital Therapeutics as Standard of Care for the Treatment of Substance Use Disorders

News for Thimble Point Acquisition Corp Stock (PEAR)